Clinical Trials Directory

Trials / Completed

CompletedNCT01556009

Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas

A Phase II Randomized, Open Label Trial Comparing the Effects of Intermittent Vismodegib Versus PDT on the Maintenance of Benefit Following 7 Months of Continuous Vismodegib Treatment in Patients With Multiple Basal Cell Carcinomas

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
24 (actual)
Sponsor
UCSF Benioff Children's Hospital Oakland · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate and compare the safety and efficacy of intermittent vismodegib and of Photodynamic Therapy (PDT).

Detailed description

This is a Phase II, 28 month, randomized, two arm multicenter clinical study design. During the initial 7 months of the study, all 24 subjects will receive vismodegib, 150mg/day. They then will be randomized in a 1:1 ratio to receive intermittent vismodegib, 150 mg/day, during months 10-13, 16-19, and 22-25 or to receive treatment with PDT at month 10 and at three month intervals thereafter. The safety and efficacy of intermittent vismodegib and of PDT will be assessed at the time of the subjects' visits to the Study Center and at the time of telephone contacts. A Data Safety Monitoring Board (DSMB) will review results for an interim analysis when 12 subjects have completed 28 months. The DSMB review will focus on adverse events and efficacy results. Subjects will be monitored for the presence of surrogate endpoint biomarkers (SEBs) at each Study visit.

Conditions

Interventions

TypeNameDescription
DRUGVismodegib150 mg per day for 7 continuous months then randomized for 3 month intervals to 28 months.
DRUGAminolevulinic acid %20 topical solution20% topical solution applied every three months from month 10, 13, 16, 19, 22. Applied and incubated for three hours.

Timeline

Start date
2012-04-01
Primary completion
2015-12-01
Completion
2015-12-01
First posted
2012-03-16
Last updated
2020-11-02
Results posted
2020-11-02

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01556009. Inclusion in this directory is not an endorsement.